In the present study, we observed that hAMSCs-CM was able to improve HFD-induced metabolic disorders by reducing weight gain, improving insulin sensitivity, alleviating hepatic steatosis, and enhancing energy expenditure. This evidence concerns the gene INS and fatty liver disease.